~

This report is for Members only | Already a Member? Sign in

To continue reading, choose your Membership package from the options below

ANNUAL MEMBERSHIP

USD 49/year
Unlimited access to my very best investment ideas:
Z

10 extensive research reports per year

Z

Updates on previous research reports

Z

Email alerts for reports and updates

Z

Archive with all past research reports

LIFETIME MEMBERSHIP

USD 999/one-off

All the benefits of the Annual Membership package, plus:

Z

4 additional investment opportunities each year, sourced from small- and mid-caps (i.e., less liquid markets)

Z

Priority booking of reader events and trips

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.